Turn Therapeutics' Third-Quarter Net Loss Widens to $6.2 Million

Turn Therapeutics Inc.'s third-quarter net loss widened to $6.2 million from $1.9 million a year earlier, as the clinical-stage biotechnology company awaits an atopic dermatitis trial readout in 2027.

For the three months ended Sept. 30, the company recorded a GAAP loss of $0.21 per basic and diluted share, compared with $0.07 per basic and diluted share in the third quarter of 2025.

Research and development expenses rose to $605,197 from $158,699 a year earlier. General and administrative expenses declined to $1.4 million from $1.8 million over the same period.

Turn Therapeutics held $10.4 million in cash and cash equivalents at Sept. 30. The company expects its available cash to fund operations into the third quarter of 2027.

Its next stated milestone is topline results from a Phase 2b trial in atopic dermatitis, expected in the first quarter of 2027.